Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Autoimmune Disorders

  Free Subscription


Articles published in J Neurol

Retrieve available abstracts of 118 articles:
HTML format
Text format



Single Articles


    October 2018
  1. MCLAUGHLIN L, Clarke L, Khalilidehkordi E, Butzkueven H, et al
    Vitamin D for the treatment of multiple sclerosis: a meta-analysis.
    J Neurol. 2018 Oct 3. pii: 10.1007/s00415-018-9074.
    PubMed     Text format     Abstract available


  2. TOMMASIN S, De Giglio L, Ruggieri S, Petsas N, et al
    Relation between functional connectivity and disability in multiple sclerosis: a non-linear model.
    J Neurol. 2018 Oct 1. pii: 10.1007/s00415-018-9075.
    PubMed     Text format     Abstract available


    September 2018
  3. PROSPERINI L, Annovazzi P, Boffa L, Buscarinu MC, et al
    No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study.
    J Neurol. 2018 Sep 26. pii: 10.1007/s00415-018-9070.
    PubMed     Text format     Abstract available


  4. TUDOR KI, Eames S, Haslam C, Chataway J, et al
    Identifying barriers to help-seeking for sexual dysfunction in multiple sclerosis.
    J Neurol. 2018 Sep 19. pii: 10.1007/s00415-018-9064.
    PubMed     Text format     Abstract available


  5. LI F, Hotter B, Swierzy M, Ismail M, et al
    Generalization after ocular onset in myasthenia gravis: a case series in Germany.
    J Neurol. 2018 Sep 17. pii: 10.1007/s00415-018-9056.
    PubMed     Text format     Abstract available


  6. FAKIH R, Matiello M, Chitnis T, Stankiewicz JM, et al
    Efficacy and safety of mycophenolate mofetil in progressive multiple sclerosis patients.
    J Neurol. 2018 Sep 10. pii: 10.1007/s00415-018-9050.
    PubMed     Text format     Abstract available


  7. GAETANI L, Prosperini L, Mancini A, Eusebi P, et al
    2017 revisions of McDonald criteria shorten the time to diagnosis of multiple sclerosis in clinically isolated syndromes.
    J Neurol. 2018 Sep 8. pii: 10.1007/s00415-018-9048.
    PubMed     Text format     Abstract available


  8. LY LT, Kreye J, Jurek B, Leubner J, et al
    Affinities of human NMDA receptor autoantibodies: implications for disease mechanisms and clinical diagnostics.
    J Neurol. 2018 Sep 5. pii: 10.1007/s00415-018-9042.
    PubMed     Text format     Abstract available


  9. CAMBRON M, Reynders T, Debruyne J, Reyngoudt H, et al
    Targeting phosphocreatine metabolism in relapsing-remitting multiple sclerosis: evaluation with brain MRI, (1)H and (31)P MRS, and clinical and cognitive testing.
    J Neurol. 2018 Sep 5. pii: 10.1007/s00415-018-9039.
    PubMed     Text format     Abstract available


    August 2018
  10. FILSER M, Schreiber H, Pottgen J, Ullrich S, et al
    The Brief International Cognitive Assessment in Multiple Sclerosis (BICAMS): results from the German validation study.
    J Neurol. 2018 Aug 31. pii: 10.1007/s00415-018-9034.
    PubMed     Text format     Abstract available


  11. BABER U, Bouley A, Egnor E, Sloane JA, et al
    Anti-JC virus antibody index changes in rituximab-treated multiple sclerosis patients.
    J Neurol. 2018 Aug 14. pii: 10.1007/s00415-018-8996.
    PubMed     Text format     Abstract available


  12. ALEKSEEVA TM, Gavrilov YV, Kreis OA, Valko PO, et al
    Fatigue in patients with myasthenia gravis.
    J Neurol. 2018 Aug 11. pii: 10.1007/s00415-018-8995.
    PubMed     Text format     Abstract available


  13. RUMPF JJ, Dietrich S, Stoppe M, Fricke C, et al
    Compromised tDCS-induced facilitation of motor consolidation in patients with multiple sclerosis.
    J Neurol. 2018 Aug 6. pii: 10.1007/s00415-018-8993.
    PubMed     Text format     Abstract available


  14. SEITZ CB, Droby A, Zaubitzer L, Kramer J, et al
    Discriminative power of intra-retinal layers in early multiple sclerosis using 3D OCT imaging.
    J Neurol. 2018 Aug 2. pii: 10.1007/s00415-018-8988.
    PubMed     Text format     Abstract available


    July 2018
  15. FROHLICH K, Winder K, Linker RA, Huhn K, et al
    Lesion correlates of secondary paroxysmal dyskinesia in multiple sclerosis.
    J Neurol. 2018 Jul 31. pii: 10.1007/s00415-018-8989.
    PubMed     Text format     Abstract available


  16. COCOZZA S, Pontillo G, Russo C, Russo CV, et al
    Cerebellum and cognition in progressive MS patients: functional changes beyond atrophy?
    J Neurol. 2018 Jul 28. pii: 10.1007/s00415-018-8985.
    PubMed     Text format     Abstract available


  17. BALLOY G, Pelletier J, Suchet L, Lebrun C, et al
    Inaugural tumor-like multiple sclerosis: clinical presentation and medium-term outcome in 87 patients.
    J Neurol. 2018 Jul 27. pii: 10.1007/s00415-018-8984.
    PubMed     Text format     Abstract available


  18. BARONE S, Caligiuri ME, Valentino P, Cherubini A, et al
    Multimodal assessment of normal-appearing corpus callosum is a useful marker of disability in relapsing-remitting multiple sclerosis: an MRI cluster analysis study.
    J Neurol. 2018 Jul 26. pii: 10.1007/s00415-018-8980.
    PubMed     Text format     Abstract available


  19. GALGANI S, Prosperini L, Haggiag S, Tortorella C, et al
    Early transient asymptomatic neutropenia associated with alemtuzumab treatment in multiple sclerosis: a case report.
    J Neurol. 2018 Jul 17. pii: 10.1007/s00415-018-8976.
    PubMed     Text format    


  20. BOST C, Chanson E, Picard G, Meyronet D, et al
    Malignant tumors in autoimmune encephalitis with anti-NMDA receptor antibodies.
    J Neurol. 2018 Jul 12. pii: 10.1007/s00415-018-8970.
    PubMed     Text format     Abstract available


  21. ALADRO Y, Lopez-Alvarez L, Sanchez-Reyes JM, Hernandez-Tamames JA, et al
    Relationship between episodic memory and volume of the brain regions of two functional cortical memory systems in multiple sclerosis.
    J Neurol. 2018 Jul 11. pii: 10.1007/s00415-018-8965.
    PubMed     Text format     Abstract available


  22. KALLWEIT U, Bassetti CLA, Oberholzer M, Fronczek R, et al
    Coexisting narcolepsy (with and without cataplexy) and multiple sclerosis : Six new cases and a literature review.
    J Neurol. 2018 Jul 4. pii: 10.1007/s00415-018-8949.
    PubMed     Text format     Abstract available


    June 2018
  23. BAJRAMI A, Pitteri M, Castellaro M, Pizzini F, et al
    The effect of fingolimod on focal and diffuse grey matter damage in active MS patients.
    J Neurol. 2018 Jun 25. pii: 10.1007/s00415-018-8952.
    PubMed     Text format     Abstract available


  24. MOTTE J, Kneiphof J, Strassburger-Krogias K, Klasing A, et al
    Detection of JC virus archetype in cerebrospinal fluid in a MS patient with dimethylfumarate treatment without lymphopenia or signs of PML.
    J Neurol. 2018 Jun 15. pii: 10.1007/s00415-018-8931.
    PubMed     Text format     Abstract available


    May 2018
  25. MARSHALL I, Thrippleton MJ, Bastin ME, Mollison D, et al
    Characterisation of tissue-type metabolic content in secondary progressive multiple sclerosis: a magnetic resonance spectroscopic imaging study.
    J Neurol. 2018 May 30. pii: 10.1007/s00415-018-8903.
    PubMed     Text format     Abstract available


  26. YAMAGUCHI H, Sakai K, Goto Y, Yamada M, et al
    Autoimmune hepatitis induced by a single injection of interferon-beta 1a in a patient with multiple sclerosis.
    J Neurol. 2018 May 29. pii: 10.1007/s00415-018-8912.
    PubMed     Text format    


  27. SANTANGELO G, Bisecco A, Trojano L, Sacco R, et al
    Cognitive performance in multiple sclerosis: the contribution of intellectual enrichment and brain MRI measures.
    J Neurol. 2018 May 26. pii: 10.1007/s00415-018-8905.
    PubMed     Text format     Abstract available


  28. ALCALA C, Gascon F, Perez-Miralles F, Gil-Perotin S, et al
    Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study.
    J Neurol. 2018 May 21. pii: 10.1007/s00415-018-8899.
    PubMed     Text format     Abstract available


  29. KOCSIK AS, Klein DE, Liedke M, Kaunzner UW, et al
    Induction of disease remission with one cycle of alemtuzumab in relapsing-remitting MS.
    J Neurol. 2018;265:1226-1229.
    PubMed     Text format     Abstract available


  30. OPFER R, Ostwaldt AC, Walker-Egger C, Manogaran P, et al
    Within-patient fluctuation of brain volume estimates from short-term repeated MRI measurements using SIENA/FSL.
    J Neurol. 2018;265:1158-1165.
    PubMed     Text format     Abstract available


  31. TALLANTYRE EC, Whittam DH, Jolles S, Paling D, et al
    Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation.
    J Neurol. 2018;265:1115-1122.
    PubMed     Text format     Abstract available


    April 2018
  32. RASUL T, Frederiksen JL
    Link between overweight/obese in children and youngsters and occurrence of multiple sclerosis.
    J Neurol. 2018 Apr 26. pii: 10.1007/s00415-018-8869.
    PubMed     Text format     Abstract available


  33. HUHN K, Bayas A, Doerck S, Frank B, et al
    Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study.
    J Neurol. 2018 Apr 25. pii: 10.1007/s00415-018-8871.
    PubMed     Text format     Abstract available


  34. TAVAZZI E, Bergsland N, Cattaneo D, Gervasoni E, et al
    Effects of motor rehabilitation on mobility and brain plasticity in multiple sclerosis: a structural and functional MRI study.
    J Neurol. 2018 Apr 7. pii: 10.1007/s00415-018-8859.
    PubMed     Text format     Abstract available


  35. CABRE P, Mejdoubi M, Jeannin S, Merle H, et al
    Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study.
    J Neurol. 2018;265:917-925.
    PubMed     Text format     Abstract available


    March 2018
  36. COGHE G, Corona F, Marongiu E, Fenu G, et al
    Fatigue, as measured using the Modified Fatigue Impact Scale, is a predictor of processing speed improvement induced by exercise in patients with multiple sclerosis: data from a randomized controlled trial.
    J Neurol. 2018 Mar 24. pii: 10.1007/s00415-018-8836.
    PubMed     Text format     Abstract available


  37. NAKKEN O, Lindstrom JC, Holmoy T
    Sex ratio in multiple sclerosis mortality over 65 years; an age-period-cohort analysis in Norway.
    J Neurol. 2018 Mar 21. pii: 10.1007/s00415-018-8832.
    PubMed     Text format     Abstract available


  38. CERONIE B, Jacobs BM, Baker D, Dubuisson N, et al
    Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells.
    J Neurol. 2018 Mar 17. pii: 10.1007/s00415-018-8830.
    PubMed     Text format     Abstract available


  39. LANZILLO R, Prosperini L, Gasperini C, Moccia M, et al
    A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study.
    J Neurol. 2018 Mar 16. pii: 10.1007/s00415-018-8831.
    PubMed     Text format     Abstract available


  40. AOYAMA S, Mori M, Uzawa A, Uchida T, et al
    Serum anti-JCV antibody indexes in Japanese patients with multiple sclerosis: elevations along with fingolimod treatment duration.
    J Neurol. 2018 Mar 12. pii: 10.1007/s00415-018-8813.
    PubMed     Text format     Abstract available


  41. DEVONSHIRE V, Phillips R, Wass H, Da Roza G, et al
    Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations.
    J Neurol. 2018 Mar 10. pii: 10.1007/s00415-018-8822.
    PubMed     Text format     Abstract available


  42. HOTTENROTT T, Schorb E, Fritsch K, Dersch R, et al
    The MRZ reaction and a quantitative intrathecal IgG synthesis may be helpful to differentiate between primary central nervous system lymphoma and multiple sclerosis.
    J Neurol. 2018 Mar 6. pii: 10.1007/s00415-018-8779.
    PubMed     Text format     Abstract available


  43. LOREFICE L, Fenu G, Pitzalis R, Scalas G, et al
    Autoimmune comorbidities in multiple sclerosis: what is the influence on brain volumes? A case-control MRI study.
    J Neurol. 2018 Mar 5. pii: 10.1007/s00415-018-8811.
    PubMed     Text format     Abstract available


  44. KANEKO A, Kaneko J, Tominaga N, Kanazawa N, et al
    Pitfalls in clinical diagnosis of anti-NMDA receptor encephalitis.
    J Neurol. 2018;265:586-596.
    PubMed     Text format     Abstract available


    February 2018
  45. BROICHER SD, Filli L, Geisseler O, Germann N, et al
    Positive effects of fampridine on cognition, fatigue and depression in patients with multiple sclerosis over 2 years.
    J Neurol. 2018 Feb 20. pii: 10.1007/s00415-018-8796.
    PubMed     Text format     Abstract available


  46. VAN DER VUURST DE VRIES RM, Mescheriakova JY, Runia TF, Siepman TAM, et al
    Smoking at time of CIS increases the risk of clinically definite multiple sclerosis.
    J Neurol. 2018 Feb 20. pii: 10.1007/s00415-018-8780.
    PubMed     Text format     Abstract available


  47. BELL JS, Spencer JI, Yates RL, DeLuca GC, et al
    The cortical blood-brain barrier in multiple sclerosis: a gateway to progression?
    J Neurol. 2018 Feb 13. pii: 10.1007/s00415-017-8727.
    PubMed     Text format    


  48. ESPOSITO F, Ferre L, Clarelli F, Rocca MA, et al
    Effectiveness and baseline factors associated to fingolimod response in a real-world study on multiple sclerosis patients.
    J Neurol. 2018 Feb 12. pii: 10.1007/s00415-018-8791.
    PubMed     Text format     Abstract available


  49. ARNETH B
    Up-to-date knowledge about the association between multiple sclerosis and the reactivation of human endogenous retrovirus infections.
    J Neurol. 2018 Feb 8. pii: 10.1007/s00415-018-8783.
    PubMed     Text format     Abstract available


  50. SOLARO C, Cella M, Signori A, Martinelli V, et al
    Identifying neuropathic pain in patients with multiple sclerosis: a cross-sectional multicenter study using highly specific criteria.
    J Neurol. 2018 Feb 5. pii: 10.1007/s00415-018-8758.
    PubMed     Text format     Abstract available


  51. KALRON A, Allali G, Achiron A
    Cerebellum and cognition in multiple sclerosis: the fall status matters.
    J Neurol. 2018 Feb 2. pii: 10.1007/s00415-018-8774.
    PubMed     Text format     Abstract available


  52. WINDER K, Linker RA, Seifert F, Deutsch M, et al
    Insular multiple sclerosis lesions are associated with erectile dysfunction.
    J Neurol. 2018 Feb 1. pii: 10.1007/s00415-018-8763.
    PubMed     Text format     Abstract available


  53. LANDFELDT E, Castelo-Branco A, Svedbom A, Lofroth E, et al
    The long-term impact of early treatment of multiple sclerosis on the risk of disability pension.
    J Neurol. 2018 Feb 1. pii: 10.1007/s00415-018-8764.
    PubMed     Text format     Abstract available


  54. FRAU J, Carai M, Coghe G, Fenu G, et al
    Long-term follow-up more than 10 years after HSCT: a monocentric experience.
    J Neurol. 2018;265:410-416.
    PubMed     Text format     Abstract available


  55. AKDAL G, Tanriverdizade T, Sengun I, Bademkiran F, et al
    Vestibular impairment in chronic inflammatory demyelinating polyneuropathy.
    J Neurol. 2018;265:381-387.
    PubMed     Text format     Abstract available


  56. WANG R, Lai XH, Liu X, Li YJ, et al
    Brain magnetic resonance-imaging findings of anti-N-methyl-D-aspartate receptor encephalitis: a cohort follow-up study in Chinese patients.
    J Neurol. 2018;265:362-369.
    PubMed     Text format     Abstract available


  57. HONGELL K, Silva DG, Ritter S, Meier DP, et al
    Efficacy and safety outcomes in vitamin D supplement users in the fingolimod phase 3 trials.
    J Neurol. 2018;265:348-355.
    PubMed     Text format     Abstract available


    January 2018
  58. VOGRIG A, Joubert B, Ducray F, Thomas L, et al
    Glioblastoma as differential diagnosis of autoimmune encephalitis.
    J Neurol. 2018 Jan 30. pii: 10.1007/s00415-018-8767.
    PubMed     Text format     Abstract available


  59. GILHUS NE, Romi F, Hong Y, Skeie GO, et al
    Myasthenia gravis and infectious disease.
    J Neurol. 2018 Jan 25. pii: 10.1007/s00415-018-8751.
    PubMed     Text format     Abstract available


  60. FIENE M, Rufener KS, Kuehne M, Matzke M, et al
    Electrophysiological and behavioral effects of frontal transcranial direct current stimulation on cognitive fatigue in multiple sclerosis.
    J Neurol. 2018 Jan 22. pii: 10.1007/s00415-018-8754.
    PubMed     Text format     Abstract available


  61. LEAVITT VM, Tosto G, Riley CS
    Cognitive phenotypes in multiple sclerosis.
    J Neurol. 2018 Jan 22. pii: 10.1007/s00415-018-8747.
    PubMed     Text format     Abstract available


  62. DI GREGORIO M, Gaetani L, Eusebi P, Floridi P, et al
    Treatment of multiple sclerosis relapses with high-dose methylprednisolone reduces the evolution of contrast-enhancing lesions into persistent black holes.
    J Neurol. 2018 Jan 11. pii: 10.1007/s00415-017-8726.
    PubMed     Text format     Abstract available


  63. MCMACKEN G, Whittaker RG, Evangelista T, Abicht A, et al
    Congenital myasthenic syndrome with episodic apnoea: clinical, neurophysiological and genetic features in the long-term follow-up of 19 patients.
    J Neurol. 2018;265:194-203.
    PubMed     Text format     Abstract available


  64. ALENDA R, Costa-Frossard L, Alvarez-Lafuente R, Espejo C, et al
    Blood lymphocyte subsets identify optimal responders to IFN-beta in MS.
    J Neurol. 2018;265:24-31.
    PubMed     Text format     Abstract available


    December 2017
  65. FRAU J, Villar LM, Sardu C, Secci MA, et al
    Intrathecal oligoclonal bands synthesis in multiple sclerosis: is it always a prognostic factor?
    J Neurol. 2017 Dec 22. pii: 10.1007/s00415-017-8716.
    PubMed     Text format     Abstract available


  66. BRENTON JN, Schreiner T, Karoscik K, Richter M, et al
    Attitudes, perceptions, and use of marijuana in youth with multiple sclerosis.
    J Neurol. 2017 Dec 22. pii: 10.1007/s00415-017-8715.
    PubMed     Text format     Abstract available


  67. SHRIBMAN S, Hasan H, Hadavi S, Giovannoni G, et al
    The BRAIN test: a keyboard-tapping test to assess disability and clinical features of multiple sclerosis.
    J Neurol. 2017 Dec 4. pii: 10.1007/s00415-017-8690.
    PubMed     Text format     Abstract available


    November 2017
  68. THALER C, Faizy TD, Sedlacik J, Bester M, et al
    The use of multiparametric quantitative magnetic resonance imaging for evaluating visually assigned lesion groups in patients with multiple sclerosis.
    J Neurol. 2017 Nov 20. doi: 10.1007/s00415-017-8683.
    PubMed     Text format     Abstract available


  69. CONRADSSON D, Ytterberg C, von Koch L, Johansson S, et al
    Changes in disability in people with multiple sclerosis: a 10-year prospective study.
    J Neurol. 2017 Nov 20. doi: 10.1007/s00415-017-8676.
    PubMed     Text format     Abstract available


  70. ELIASDOTTIR O, Hildeman A, Longfils M, Nerman O, et al
    A nationwide survey of the influence of month of birth on the risk of developing multiple sclerosis in Sweden and Iceland.
    J Neurol. 2017 Nov 20. doi: 10.1007/s00415-017-8665.
    PubMed     Text format     Abstract available


  71. RUPRECHT K, Wildemann B, Jarius S
    Low intrathecal antibody production despite high seroprevalence of Epstein-Barr virus in multiple sclerosis: a review of the literature.
    J Neurol. 2017 Nov 2. doi: 10.1007/s00415-017-8656.
    PubMed     Text format     Abstract available


    October 2017
  72. COMI G, Patti F, Rocca MA, Mattioli FC, et al
    Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study).
    J Neurol. 2017 Oct 23. doi: 10.1007/s00415-017-8642.
    PubMed     Text format     Abstract available


  73. PARDO G, Jones DE
    Correction to: The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations.
    J Neurol. 2017 Oct 23. doi: 10.1007/s00415-017-8633.
    PubMed     Text format     Abstract available


  74. ABBOUD H, Rossman I, Mealy MA, Hill E, et al
    Neuronal autoantibodies: differentiating clinically relevant and clinically irrelevant results.
    J Neurol. 2017 Oct 3. doi: 10.1007/s00415-017-8627.
    PubMed     Text format     Abstract available


    September 2017
  75. WANG L, Zhang S, Xi J, Li W, et al
    Efficacy and safety of tacrolimus for myasthenia gravis: a systematic review and meta-analysis.
    J Neurol. 2017 Sep 18. doi: 10.1007/s00415-017-8616.
    PubMed     Text format     Abstract available


  76. LOREFICE L, Coghe G, Fenu G, Porta M, et al
    'Timed up and go' and brain atrophy: a preliminary MRI study to assess functional mobility performance in multiple sclerosis.
    J Neurol. 2017 Sep 11. doi: 10.1007/s00415-017-8612.
    PubMed     Text format     Abstract available


  77. PARDO G, Jones DE
    The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations.
    J Neurol. 2017 Sep 6. doi: 10.1007/s00415-017-8594.
    PubMed     Text format     Abstract available


    August 2017
  78. LATTANZI S, Danni M, Taffi R, Cerqua R, et al
    Persistence to oral disease-modifying therapies in multiple sclerosis patients.
    J Neurol. 2017 Aug 22. doi: 10.1007/s00415-017-8595.
    PubMed     Text format     Abstract available


  79. HRASTELJ J, Robertson N
    Genetics of disease severity in multiple sclerosis, Alzheimer's disease, and Huntington's disease: rejuvenating genome-wide association studies.
    J Neurol. 2017 Aug 7. doi: 10.1007/s00415-017-8584.
    PubMed     Text format    


  80. FINKE C, Bartels F, Lutt A, Pruss H, et al
    High prevalence of neuronal surface autoantibodies associated with cognitive deficits in cancer patients.
    J Neurol. 2017 Aug 7. doi: 10.1007/s00415-017-8582.
    PubMed     Text format     Abstract available


    July 2017
  81. EICHINGER P, Wiestler H, Zhang H, Biberacher V, et al
    A novel imaging technique for better detecting new lesions in multiple sclerosis.
    J Neurol. 2017 Jul 29. doi: 10.1007/s00415-017-8576.
    PubMed     Text format     Abstract available


  82. SCHOSER B, Eymard B, Datt J, Mantegazza R, et al
    Erratum to: Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer.
    J Neurol. 2017 Jul 10. doi: 10.1007/s00415-017-8556.
    PubMed     Text format    


    June 2017
  83. CASEY JP, Hirouchi T, Hisatsune C, Lynch B, et al
    A novel gain-of-function mutation in the ITPR1 suppressor domain causes spinocerebellar ataxia with altered Ca2+ signal patterns.
    J Neurol. 2017 Jun 15. doi: 10.1007/s00415-017-8545.
    PubMed     Text format     Abstract available


  84. SCHOSER B, Eymard B, Datt J, Mantegazza R, et al
    Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer.
    J Neurol. 2017 Jun 12. doi: 10.1007/s00415-017-8541.
    PubMed     Text format     Abstract available


  85. HAGSTROM IT, Schneider R, Bellenberg B, Salmen A, et al
    Relevance of early cervical cord volume loss in the disease evolution of clinically isolated syndrome and early multiple sclerosis: a 2-year follow-up study.
    J Neurol. 2017 Jun 9. doi: 10.1007/s00415-017-8537.
    PubMed     Text format     Abstract available


    May 2017
  86. BRITZE J, Pihl-Jensen G, Frederiksen JL
    Retinal ganglion cell analysis in multiple sclerosis and optic neuritis: a systematic review and meta-analysis.
    J Neurol. 2017 May 31. doi: 10.1007/s00415-017-8531.
    PubMed     Text format     Abstract available


  87. DIBLEY L, Coggrave M, McClurg D, Woodward S, et al
    "It's just horrible": a qualitative study of patients' and carers' experiences of bowel dysfunction in multiple sclerosis.
    J Neurol. 2017 May 26. doi: 10.1007/s00415-017-8527.
    PubMed     Text format     Abstract available


  88. RATH J, Mauritz M, Zulehner G, Hilger E, et al
    Iodinated contrast agents in patients with myasthenia gravis: a retrospective cohort study.
    J Neurol. 2017 May 26. doi: 10.1007/s00415-017-8518.
    PubMed     Text format     Abstract available


  89. RIVIERE E, Cohen Aubart F, Maisonobe T, Maurier F, et al
    Clinicopathological features of multiple mononeuropathy associated with systemic lupus erythematosus: a multicenter study.
    J Neurol. 2017 May 23. doi: 10.1007/s00415-017-8519.
    PubMed     Text format     Abstract available


  90. FOULON S, Maura G, Dalichampt M, Alla F, et al
    Prevalence and mortality of patients with multiple sclerosis in France in 2012: a study based on French health insurance data.
    J Neurol. 2017 May 17. doi: 10.1007/s00415-017-8513.
    PubMed     Text format     Abstract available


  91. CORDTS I, Bodart N, Hartmann K, Karagiorgou K, et al
    Screening for lipoprotein receptor-related protein 4-, agrin-, and titin-antibodies and exploring the autoimmune spectrum in myasthenia gravis.
    J Neurol. 2017 May 17. doi: 10.1007/s00415-017-8514.
    PubMed     Text format     Abstract available


  92. LATTANZI S, Cagnetti C, Danni M, Provinciali L, et al
    Oral and intravenous steroids for multiple sclerosis relapse: a systematic review and meta-analysis.
    J Neurol. 2017 May 10. doi: 10.1007/s00415-017-8505.
    PubMed     Text format     Abstract available


    April 2017
  93. HARDING K, Tilling K, MacIver C, Willis M, et al
    Seasonal variation in multiple sclerosis relapse.
    J Neurol. 2017 Apr 19. doi: 10.1007/s00415-017-8485.
    PubMed     Text format     Abstract available


  94. SARTORI A, Abdoli M, Freedman MS
    Can we predict benign multiple sclerosis? Results of a 20-year long-term follow-up study.
    J Neurol. 2017 Apr 17. doi: 10.1007/s00415-017-8487.
    PubMed     Text format     Abstract available


  95. HAINLINE C, Rizzo JR, Hudson TE, Dai W, et al
    Capturing saccades in multiple sclerosis with a digitized test of rapid number naming.
    J Neurol. 2017 Apr 7. doi: 10.1007/s00415-017-8484.
    PubMed     Text format     Abstract available


  96. CHOI HA, Lee MJ, Chung CS
    Characteristics of hypertrophic pachymeningitis in patients with granulomatosis with polyangiitis.
    J Neurol. 2017;264:724-732.
    PubMed     Text format     Abstract available


  97. BARTOLINI L, Muscal E
    Differences in treatment of anti-NMDA receptor encephalitis: results of a worldwide survey.
    J Neurol. 2017;264:647-653.
    PubMed     Text format     Abstract available


    March 2017
  98. HONG Y, Skeie GO, Zisimopoulou P, Karagiorgou K, et al
    Juvenile-onset myasthenia gravis: autoantibody status, clinical characteristics and genetic polymorphisms.
    J Neurol. 2017 Mar 31. doi: 10.1007/s00415-017-8478.
    PubMed     Text format     Abstract available


  99. PREZIOSA P, Martinelli V, Ferre L, Guaschino C, et al
    Moyamoya disease mimicking the first attack of multiple sclerosis.
    J Neurol. 2017 Mar 17. doi: 10.1007/s00415-017-8458.
    PubMed     Text format    


  100. KHAN F, Amatya B, Galea MP, Gonzenbach R, et al
    Neurorehabilitation: applied neuroplasticity.
    J Neurol. 2017;264:603-615.
    PubMed     Text format     Abstract available


    February 2017
  101. MALONEY E, Molloy A, Al Hussona M, O'Donnell L, et al
    Natalizumab-associated progressive multifocal leukoencephalopathy: successful treatment without plasma exchange and its associated risks.
    J Neurol. 2017;264:401-403.
    PubMed     Text format    


    January 2017
  102. BIANCHI A, Bartolini E, Melani F, Guerrini R, et al
    Isolated recurrent myelitis in a 7-year-old child with serum aquaporin-4 IgG antibodies.
    J Neurol. 2017;264:179-181.
    PubMed     Text format    


    December 2016
  103. GIORLI E, Franciotta D, Beronio A, Amodeo C, et al
    Late AQP4-IgG seroconversion and shrinking of brainstem MRI lesions in a patient with overlapping CIS/NMOSD.
    J Neurol. 2016;263:2549-2551.
    PubMed     Text format    


  104. HUSS AM, Halbgebauer S, Ockl P, Trebst C, et al
    Importance of cerebrospinal fluid analysis in the era of McDonald 2010 criteria: a German-Austrian retrospective multicenter study in patients with a clinically isolated syndrome.
    J Neurol. 2016;263:2499-2504.
    PubMed     Text format     Abstract available


  105. HUANG Q, Wu Y, Qin R, Wei X, et al
    Clinical characteristics and outcomes between children and adults with anti-N-Methyl-D-Aspartate receptor encephalitis.
    J Neurol. 2016;263:2446-2455.
    PubMed     Text format     Abstract available


    October 2016
  106. PIETRZAK K, Grzybowski A, Kaczmarczyk J
    Georges Guillain (1876-1961).
    J Neurol. 2016;263:2148-9.
    PubMed     Text format    


  107. ABSINTA M, Reich DS, Filippi M
    Spring cleaning: time to rethink imaging research lines in MS?
    J Neurol. 2016;263:1893-902.
    PubMed     Text format     Abstract available


    September 2016
  108. MAILLART E, Papeix C, Mellerio C, Bertrand A, et al
    Extensive and severe CNS demyelination associated with golimumab therapy.
    J Neurol. 2016;263:1869-71.
    PubMed     Text format    


  109. LOZERON P, Ribrag V, Adams D, Brisset M, et al
    Is distal motor and/or sensory demyelination a distinctive feature of anti-MAG neuropathy?
    J Neurol. 2016;263:1761-70.
    PubMed     Text format     Abstract available


  110. ANNOVAZZI P, Capobianco M, Moiola L, Patti F, et al
    Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study.
    J Neurol. 2016;263:1727-35.
    PubMed     Text format     Abstract available


    August 2016
  111. ZURAWSKI J, Flinn A, Sklover L, Sloane JA, et al
    Relapse frequency in transitioning from natalizumab to dimethyl fumarate: assessment of risk factors.
    J Neurol. 2016;263:1511-7.
    PubMed     Text format     Abstract available


    July 2016
  112. ZHOU H, Zhao S, Yin D, Chen X, et al
    Optic neuritis: a 5-year follow-up study of Chinese patients based on aquaporin-4 antibody status and ages.
    J Neurol. 2016;263:1382-9.
    PubMed     Text format     Abstract available


  113. JEONG IH, Kim HJ, Kim NH, Jeong KS, et al
    Subclinical primary retinal pathology in neuromyelitis optica spectrum disorder.
    J Neurol. 2016;263:1343-8.
    PubMed     Text format     Abstract available


  114. BALK LJ, Cruz-Herranz A, Albrecht P, Arnow S, et al
    Timing of retinal neuronal and axonal loss in MS: a longitudinal OCT study.
    J Neurol. 2016;263:1323-31.
    PubMed     Text format     Abstract available


  115. HAVRDOVA E, Belova A, Goloborodko A, Tisserant A, et al
    Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study.
    J Neurol. 2016;263:1287-95.
    PubMed     Text format     Abstract available


    June 2016
  116. BRIER MR, Day GS, Snyder AZ, Tanenbaum AB, et al
    N-methyl-D-aspartate receptor encephalitis mediates loss of intrinsic activity measured by functional MRI.
    J Neurol. 2016;263:1083-91.
    PubMed     Text format     Abstract available


  117. GRIMM A, Vittore D, Schubert V, Rasenack M, et al
    Ultrasound aspects in therapy-naive CIDP compared to long-term treated CIDP.
    J Neurol. 2016;263:1074-82.
    PubMed     Text format     Abstract available


    May 2016
  118. VINJAM MR, Shanmugarajah P, Ford HL
    Ophthalmoplegia heralding the onset of anti-amphiphysin related paraneoplastic stiff person syndrome.
    J Neurol. 2016;263:1017-8.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: